Abbreviated Reports May Be Submitted For Studies Not Central To Efficacy
Executive Summary
Abbreviated data reports may be submitted for efficacy, safety and pharmacology studies that are not central to efficacy claims for a specific indication, FDA indicated in its guidance for industry on "Submission of Abbreviated Reports and Synopses in Support of Marketing Applications."